Phagocytosis checkpoints as new targets for cancer immunotherapy

Mingye Feng, Wen Jiang, Y S Betty Kim, Cheng Cheng Zhang, Yang Xin Fu, Irving L. Weissman

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Cancer immunotherapies targeting adaptive immune checkpoints have substantially improved patient outcomes across multiple metastatic and treatment-refractory cancer types. However, emerging studies have demonstrated that innate immune checkpoints, which interfere with the detection and clearance of malignant cells through phagocytosis and suppress innate immune sensing, also have a key role in tumour-mediated immune escape and might, therefore, be potential targets for cancer immunotherapy. Indeed, preclinical studies and early clinical data have established the promise of targeting phagocytosis checkpoints, such as the CD47–signal-regulatory protein α (SIRPα) axis, either alone or in combination with other cancer therapies. In this Review, we highlight the current understanding of how cancer cells evade the immune system by disrupting phagocytic clearance and the effect of phagocytosis checkpoint blockade on induction of antitumour immune responses. Given the role of innate immune cells in priming adaptive immune responses, an improved understanding of the tumour-intrinsic processes that inhibit essential immune surveillance processes, such as phagocytosis and innate immune sensing, could pave the way for the development of highly effective combination immunotherapy strategies that modulate both innate and adaptive antitumour immune responses.

Original languageEnglish (US)
JournalNature Reviews Cancer
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Phagocytosis
Immunotherapy
Neoplasms
Adaptive Immunity
Tumor Escape
Cytophagocytosis
Immune System
Therapeutics
Proteins

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Phagocytosis checkpoints as new targets for cancer immunotherapy. / Feng, Mingye; Jiang, Wen; Kim, Y S Betty; Zhang, Cheng Cheng; Fu, Yang Xin; Weissman, Irving L.

In: Nature Reviews Cancer, 01.01.2019.

Research output: Contribution to journalReview article

Feng, Mingye ; Jiang, Wen ; Kim, Y S Betty ; Zhang, Cheng Cheng ; Fu, Yang Xin ; Weissman, Irving L. / Phagocytosis checkpoints as new targets for cancer immunotherapy. In: Nature Reviews Cancer. 2019.
@article{7ed2f82dde864de9836682c5aca1d1e6,
title = "Phagocytosis checkpoints as new targets for cancer immunotherapy",
abstract = "Cancer immunotherapies targeting adaptive immune checkpoints have substantially improved patient outcomes across multiple metastatic and treatment-refractory cancer types. However, emerging studies have demonstrated that innate immune checkpoints, which interfere with the detection and clearance of malignant cells through phagocytosis and suppress innate immune sensing, also have a key role in tumour-mediated immune escape and might, therefore, be potential targets for cancer immunotherapy. Indeed, preclinical studies and early clinical data have established the promise of targeting phagocytosis checkpoints, such as the CD47–signal-regulatory protein α (SIRPα) axis, either alone or in combination with other cancer therapies. In this Review, we highlight the current understanding of how cancer cells evade the immune system by disrupting phagocytic clearance and the effect of phagocytosis checkpoint blockade on induction of antitumour immune responses. Given the role of innate immune cells in priming adaptive immune responses, an improved understanding of the tumour-intrinsic processes that inhibit essential immune surveillance processes, such as phagocytosis and innate immune sensing, could pave the way for the development of highly effective combination immunotherapy strategies that modulate both innate and adaptive antitumour immune responses.",
author = "Mingye Feng and Wen Jiang and Kim, {Y S Betty} and Zhang, {Cheng Cheng} and Fu, {Yang Xin} and Weissman, {Irving L.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1038/s41568-019-0183-z",
language = "English (US)",
journal = "Nature Reviews Cancer",
issn = "1474-175X",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Phagocytosis checkpoints as new targets for cancer immunotherapy

AU - Feng, Mingye

AU - Jiang, Wen

AU - Kim, Y S Betty

AU - Zhang, Cheng Cheng

AU - Fu, Yang Xin

AU - Weissman, Irving L.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Cancer immunotherapies targeting adaptive immune checkpoints have substantially improved patient outcomes across multiple metastatic and treatment-refractory cancer types. However, emerging studies have demonstrated that innate immune checkpoints, which interfere with the detection and clearance of malignant cells through phagocytosis and suppress innate immune sensing, also have a key role in tumour-mediated immune escape and might, therefore, be potential targets for cancer immunotherapy. Indeed, preclinical studies and early clinical data have established the promise of targeting phagocytosis checkpoints, such as the CD47–signal-regulatory protein α (SIRPα) axis, either alone or in combination with other cancer therapies. In this Review, we highlight the current understanding of how cancer cells evade the immune system by disrupting phagocytic clearance and the effect of phagocytosis checkpoint blockade on induction of antitumour immune responses. Given the role of innate immune cells in priming adaptive immune responses, an improved understanding of the tumour-intrinsic processes that inhibit essential immune surveillance processes, such as phagocytosis and innate immune sensing, could pave the way for the development of highly effective combination immunotherapy strategies that modulate both innate and adaptive antitumour immune responses.

AB - Cancer immunotherapies targeting adaptive immune checkpoints have substantially improved patient outcomes across multiple metastatic and treatment-refractory cancer types. However, emerging studies have demonstrated that innate immune checkpoints, which interfere with the detection and clearance of malignant cells through phagocytosis and suppress innate immune sensing, also have a key role in tumour-mediated immune escape and might, therefore, be potential targets for cancer immunotherapy. Indeed, preclinical studies and early clinical data have established the promise of targeting phagocytosis checkpoints, such as the CD47–signal-regulatory protein α (SIRPα) axis, either alone or in combination with other cancer therapies. In this Review, we highlight the current understanding of how cancer cells evade the immune system by disrupting phagocytic clearance and the effect of phagocytosis checkpoint blockade on induction of antitumour immune responses. Given the role of innate immune cells in priming adaptive immune responses, an improved understanding of the tumour-intrinsic processes that inhibit essential immune surveillance processes, such as phagocytosis and innate immune sensing, could pave the way for the development of highly effective combination immunotherapy strategies that modulate both innate and adaptive antitumour immune responses.

UR - http://www.scopus.com/inward/record.url?scp=85071911092&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071911092&partnerID=8YFLogxK

U2 - 10.1038/s41568-019-0183-z

DO - 10.1038/s41568-019-0183-z

M3 - Review article

C2 - 31462760

AN - SCOPUS:85071911092

JO - Nature Reviews Cancer

JF - Nature Reviews Cancer

SN - 1474-175X

ER -